{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:37:36Z","timestamp":1794281856731,"version":"4.9.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The association between pre-existing cardiovascular disease (CVD) and the development of cardiovascular adverse events (CVAE) during Bruton tyrosine kinase inhibitor (BTKi) therapy is not well established. We compared the rate of CVAE, such as new onset or worsening atrial fibrillation (AF), supraventricular tachycardia, ventricular tachycardia, hypertension, myocardial infarction, and sudden cardiac death, between individuals with and without pre-existing CVD, during BTKi treatment. Secondary objectives were to compare the outcomes of patients treated with first generation BTKi versus second generation BTKi and characterize management decisions. A single-center retrospective review was conducted on patients treated with BTKi from 2013 to 2022 at Beth Israel Deaconess Medical Center. Adjusted logistic regression analyses were performed to evaluate the association between pre-existing CVD and CVAE. In this cohort, 11 out of 54 patients (20.4%) with pre-existing CVD developed CVAE, compared to 11 out of 135 patients (8.1%) without pre-existing CVD [age- and sex-adjusted OR 2.79; 95% CI (1.09, 7.25), P\u2005=\u2005.03]. Patients with pre-existing CVD had higher odds of developing new or worsening AF [age- and sex-adjusted OR 3.36; 95% CI (1.09, 10.71), P\u2005=\u2005.03]. Results remained robust after further\u00a0adjustment of comorbidities, type of BTKi, and baseline medications. These results highlight the need for standardized approaches to prevent and promptly detect CVAE during BTKi treatment, particularly in patients with pre-existing CVD.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae229","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T14:41:50Z","timestamp":1725806510000},"source":"Crossref","is-referenced-by-count":9,"title":["Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-4380","authenticated-orcid":false,"given":"Maria J","family":"Fernandez Turizo","sequence":"first","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cancan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Yankama","sequence":"additional","affiliation":[{"name":"Department of Data Analytics and Biostatistics, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Von Keudell","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Sermer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mej\u00edas-De Jes\u00fas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-9918","authenticated-orcid":false,"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Section, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"issue":"31","key":"2025030711213546800_CIT0001","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025030711213546800_CIT0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients","volume":"5","author":"Diamond","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2025030711213546800_CIT0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"25","key":"2025030711213546800_CIT0004","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"2025030711213546800_CIT0005","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025030711213546800_CIT0006","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025030711213546800_CIT0007","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2025030711213546800_CIT0008","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025030711213546800_CIT0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardio-oncology (London, England)"},{"issue":"10","key":"2025030711213546800_CIT0010","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"Kaptoge","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"25","key":"2025030711213546800_CIT0011","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2025030711213546800_CIT0012","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/01.CIR.98.21.2334","article-title":"Sudden cardiac death","volume":"98","author":"Zipes","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"2025030711213546800_CIT0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.15420\/aer.2016:11:2","article-title":"A clinical perspective on sudden cardiac death","volume":"5","author":"Katritsis","year":"2016","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"1","key":"2025030711213546800_CIT0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10840-022-01392-w","article-title":"Preventive substrate ablation in chronic post-myocardial infarction patients with high-risk scar characteristics for ventricular arrhythmias: rationale and design of PREVENT-VT study","volume":"66","author":"Falasconi","year":"2022","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"2025030711213546800_CIT0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1471-2288-14-137","article-title":"Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints","volume":"14","author":"Van Der Ploeg","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"2025030711213546800_CIT0016","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2025030711213546800_CIT0017","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1146\/annurev.immunol.21.120601.141018","article-title":"B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor","volume":"21","author":"Chiorazzi","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2025030711213546800_CIT0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2025030711213546800_CIT0019","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2025030711213546800_CIT0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025030711213546800_CIT0021","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2025030711213546800_CIT0022","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"2025030711213546800_CIT0023","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"2025030711213546800_CIT0024","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2025030711213546800_CIT0025","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/cancers11121834","article-title":"Overcoming ibrutinib resistance in chronic lymphocytic leukemia","volume":"11","author":"Pu\u0142a","year":"2019","journal-title":"Cancers"},{"issue":"12","key":"2025030711213546800_CIT0026","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol."},{"issue":"25","key":"2025030711213546800_CIT0027","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"2025030711213546800_CIT0028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2025030711213546800_CIT0029","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"issue":"3","key":"2025030711213546800_CIT0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-Kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"issue":"1","key":"2025030711213546800_CIT0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"15_suppl","key":"2025030711213546800_CIT0032","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2021.39.15_suppl.7500","article-title":"First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"31","key":"2025030711213546800_CIT0033","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025030711213546800_CIT0034","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"18","key":"2025030711213546800_CIT0035","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"2025030711213546800_CIT0036","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2023-174289","article-title":"Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL)","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae229\/59038435\/oyae229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae229\/59038435\/oyae229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:21:53Z","timestamp":1741346513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae229\/7750736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae229","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,8]]},"article-number":"oyae229"}}